logo
logo
Sign in

Doxorubicin Market Analysis, Cost, Competition, Applications, Gross Margin, Outstanding Growth

avatar
Sapana Supekar
Doxorubicin Market Analysis, Cost, Competition, Applications, Gross Margin, Outstanding Growth

Doxorubicin Market Analysis

The global doxorubicin market size is projected to have a steady growth rate at a whopping 6.5% CAGR over the forecast period (2016-2023). Doxorubicin or anthracycline is a form of chemotherapy medicine that is used for diminishing or reducing growth of cancer cells via blocking the topo isomerase enzyme. This drug is utilized alone or together with other drugs for treating various types of cancers such as ovarian, stomach, bladder, lung, breast, non-Hodgkin and Hodgkin lymphomas, neuroblastoma and specific forms of leukemia. The treatment rests upon the cancer type being treated, how well a patient responds to the medicine and other forms of drugs that the patient takes at the time of the treatment. Doxorubicin comes in both lyophilized power form and injection solution. It is generally administered intravenously through central venous catheters (CVC) or peripheral inserted central line catheters (PICC).

There are abundant factors that is propelling the growth of the doxorubicin market. These factors as per the MRFR (Market Research Future) report include increasing prevalence of various forms of cancer, boost in geriatric population, growing awareness of cancer treatment and inclusion of the drug in different applications such as AIDS-related Kaposi Sarcoma and neuroblastoma, growing cancer treatment awareness programs, large presence of ablation and surgical centers and technological advancements. On the contrary stringent regulatory authorities, various cost suppression measures undertaken by different governments and numerous side effects resulting from doxorubicin are factors that are likely to hamper the growth of the doxorubicin market. Some of the common side effects of taking doxorubicin include inflammation of the mouth, rash, vomiting, bone marrow suppression, hair loss, allergic reactions namely anaphylaxis, damage of tissue owing to the position of the injection, heart damage, treatment associated to leukemia and radiation recall. All these side effects and more are affecting the doxorubicin market growth.

Avail Free Sample Copy at https://www.marketresearchfuture.com/sample_request/7376

Doxorubicin Market Segmentation

MRFR report offers a broad segmental analysis of the doxorubicin market on the basis of application and distribution channel.

Based on application, the doxorubicin market is segmented into leukemia, ovarian cancer, stomach cancer, prostate cancer, bone sarcoma, breast cancer, gastric cancer, liver cancer and others. Of these, prostate and breast cancer will have the largest share in the market over the forecast period.

Based on distribution channel, the doxorubicin market is segmented into retail pharmacy, hospital pharmacy and others. Of these, hospital pharmacy is projected to lead the market over the forecast period.

Doxorubicin Market Regional Analysis

By region, the doxorubicin market covers growth opportunities and latest trends across Americas, the Middle East and Africa, Europe and Asia Pacific. Of these, the Americas will remain the vital contributor in the market over the forecast period. Factors attributed for the market growth in this region include favorable regulatory authorities and reimbursement, awareness about cancer treatment, increase in cancer cases and presence of leading manufacturers. The doxorubicin market in Europe will account for the second major share owing to rising healthcare expenditure and increasing pool of cancer patients. In the APAC region, the doxorubicin market is projected to grow at the fastest pace over the forecast period. This is on account of growing geriatric population especially in China and India, growing number of manufacturers looking for opportunities in developing countries, government investment and initiatives for the healthcare sector development and increasing cancer treatment awareness programs. On the other hand, the doxorubicin market in the Middle East and Africa is prognosticated to have minimal share over the forecast period.

Doxorubicin Market Key Players

Leading players profiled in the doxorubicin market include GLENMARK PHARMACEUTICALS LTD, Teva Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Sandoz, Novartis AG, Accord Healthcare, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Pfizer, Inc, and various others.

Browse Complete Report with TOC at https://www.marketresearchfuture.com/reports/doxorubicin-market-7376

Doxorubicin Industry News

March 2019 - SourcingLink.net, Inc. (SNET) has lately revealed the news of entering into a worldwide exclusive licensing agreement with leading biopharmaceutical company, NanoSmart Pharmaceuticals, Inc. This agreement has been made for the right of utilizing nanoparticle platform technologies of NanoSmart for developing and commercializing doxorubicin’s improved formulations to treat human cancers. It will impact countless cancer patients all across the world and also offer the increasing global cancer population with enhanced therapy options, including patients with unmet rare cancer needs.

collect
0
avatar
Sapana Supekar
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more